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Background/aim: Intravesical BCG treatment fails inexplicably in 30%–45% of patients for high-grade nonmuscle-invasive bladder
cancer (NMIBC). We aimed to investigate the role of PD-1/PD-L1 interaction on BCG failure of high-grade NMIBC and to identify
biomarkers for predicting BCG responsive cases.
Materials and methods: Thirty BCG responsive and 29 nonresponsive NMIBCs were included in the study. Expressions of PDL1(SP-263), MSH2, MSH6, PMS2, and MLH1 were evaluated on pre- and post-BCG transurethral resection (TUR-B) specimens by
immunohistochemistry. PD-L1(SP-263) expression was categorised as negative/low, high. DNA mismatch repair protein (MMR)
expressions were classified as “reduced” if ≤30% of nuclei stained, “preserved” if >30% of nuclei stained. Microsatellite instability (MSI)
testing was performed by PCR using five mononucleotide markers.
Results: Reduced DNA MMR protein expression was found to be significantly higher in the pretreatment biopsies of BCG-responsive
group than the BCG nonresponsive tumour group (p = 0.022). PD-L1 expression did not show any significant difference between the
pre- and posttreatment TUR-B specimens of the BCG nonresponsive tumour group or between the pretreatment TUR-B specimens of
BCG nonresponsive and the BCG responsive groups (p = 0.508, p = 0.708, respectively).
Conclusion: Immune escape of tumour cells by PD-1/PD-L1 interaction does not seem to have any role in BCG failure of NMIBCs.
Reduced MMR expression may help to determine cases that will respond well to BCG therapy. A better antitumour activity of BCG
in NMIBCs with reduced MMR expression may be related to the ongoing accumulation of cancer neoantigens in correlation with
increased tumour mutation load as a result of DNA repair defects.
Key words: Nonmuscle-invasive bladder carcinoma, microsatellite instability, mismatch repair, PD-L1, immunotherapy, BCG therapy

1. Introduction
Bladder cancer is the 9th most common malignancy
worldwide [1]. Most of them (70%–80%) are nonmuscleinvasive urothelial carcinomas and conservative
approaches are applied to prevent tumour recurrence
or progression [2]. Instillation of intravesical Bacillus
Calmette-Guerin (BCG) following transurethral resection
is the gold standard treatment approach for high-risk
nonmuscle-invasive bladder carcinoma (NMIBC) [3,4].
However, this treatment fails in 30%–45% of patients,
and the lack of another effective conservative secondline treatment option for this patient group raises the
requirement of radical cystectomy, which is a radical
therapeutic option with significant morbidity and
mortality rates [3]. This leads to search biomarkers

to predict BCG response or alternative conservative
therapies for BCG nonresponders.
After intravesical instillation of BCG, it binds to the
urothelial cells via extracellular matrix glycoproteins
such as fibronectin and integrins. It is followed by
cellular internalization. This leads to the induction of
innate immunity by cytokines such as interleukin-1
(IL-1), interleukin-2 (IL-2), interleukin-6 (IL6), interleukin-8 (IL-8), tumour necrosis factor- α
(TNF-α), interferon-ɣ (IFN-ɣ) [4]. In addition to this
nonspecific inflammatory response, a more specific,
adaptive immune response is triggered by the antigen
presentation to T cells [5]. The antitumour effects of
BCG depend on the activation of both CD4+ and CD8+
T cells [4,6].
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Programmed death-1 (PD-1) is expressed on activated T,
B, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are
two ligands of PD-1. PD-L1 is broadly expressed on T and B
cells, other immune cells, epithelial, endothelial, and tumour
cells. Engagement of PD-1 by PD-L1 leads to the inhibition
of T-cell-mediated immune responses via inhibition of the
Ras-Raf-MEK-ERK and PI3K-AKT cascades in T cells [7].
In malignancies, tumour cells express PD-L1 to escape from
the immune response [7]. Increased expression of PD-L1
on tumour cells or tumour infiltrating lymphocytes (TILs)
leads to exhaustion of T cells. Immune checkpoint inhibitors
(ICIs) that block PD-1/PD-L1 interaction reactivate the T
cell response against tumour cells [8].
Failure in BCG treatment evokes a hypothesis that
tumour cells may develop some mechanisms to escape
from the immune system and this raises the question
of whether PD-1/PD-L1 interaction has a role in this
immune escape mechanism and whether the blockage of
this pathway may be a solution for BCG nonresponders.
The DNA “mismatch” repair (MMR) system repairs
errors that occur during DNA replication and sustains
mutation rates at a low level. In eukaryotes, the DNA
MMR system has two heterodimers consisting of MutS
protein homologue 2 (MSH2)/MutS protein homologue
6 (MSH6) and MutL homologue 1 (MLH1)/PMS1
homologue 2 (PMS2) [9]. DNA MMR proteins recognize
the mismatched nucleotide in the newly synthesized
strand and then remove the mismatched nucleotide
[10]. There are regions called “microsatellites” where
DNA polymerases are more prone to make mistakes.
Microsatellites are defined as repeats (usually 10–60 times)
of the same base or sequence of bases, ranging in length
from one to six or more base pairs. Thus, defects in the
DNA MMR system cause DNA strands with mismatched
nucleotides, the status of high microsatellite instability
(MSI-H), and the increased mutational burden in such
tumours create neoantigens which cause more immune
response. Therefore, MSI-H tumours have significant
upregulation of PD-1 and PD-L1, enabling tumour cells’
immune escape and ICI therapy (anti-PD1, anti-PD-L1) is
found more effective in MSI-H cases [9].
This study aimed to investigate the role of PD-1/PDL1 interaction on BCG failure of high-grade NMIBC and
to identify biomarkers for predicting NMIBC cases that
will not respond to BCG therapy by focusing on the MSI
status/DNA MMR gene expression of these tumours. This
is the first study in the literature that deals with all these
parameters together in BCG nonresponsive cases.
2. Material and methods
2.1. Patients and samples
Our study was designed retrospectively and included 59
nonmuscle invasive high-grade urothelial carcinoma

cases (Ta, T1), who were diagnosed and followed up at
Ankara University, School of Medicine, Departments of
Pathology and Urology, between 2005 and 2018. All the
patients had received intravesical BCG therapy and the
median follow-up period of the patients was 53 (range
12 to 156) months. “BCG nonresponsive” patient group
was classified according to the criteria specified in the
European Association of Urology Guidelines in 2020 [11]
as follows: 21 BCG-refractory tumours, 7 progressive
tumours (muscle-invasive bladder cancer at any time
after TUR-B), 1 BCG-relapsing tumour (recurrence
of high-grade tumour after BCG maintenance). In the
BCG nonresponsive group, both pretreatment and
posttreatment TUR-B specimens; in the BCG responsive
group, only pretreatment TUR-B specimens were taken
into consideration. However, posttreatment TUR-B
specimens of 2 BCG nonresponsive patients could not be
reached. Inclusion and exclusion criteria of the cases were
detailed in the flow chart (Figure 1).
Hematoxylin and eosin (H&E)-stained sections were
reviewed according to the tumour type, histological
variant, histological grade (low, high), degree of nuclear
pleomorphism (mild, prominent), the extent of invasion
(1 focus: focal, >1 focus: multifocal), long diameter of
largest invasion focus (<2mm, ≥2mm), depth of lamina
propria invasion determined according to the muscularis
mucosa invasion (superficial lamina propria, deep lamina
propria invasion), presence of carcinoma in situ, and
density of tumour-associated inflammatory cells (IC).
Tumours were graded according to WHO 2016 grading
system. And then, formalin-fixed paraffin-embedded
(FFPE) blocks that best represent the tumour were selected
for immunohistochemistry (IHC) and polymerase chain
reaction (PCR) based MSI testing.
2.2. Immunohistochemistry
H&E staining and immunostaining were performed on 4
µm thick consecutive sections. All immunohistochemical
staining was carried out on a Benchmark Ultra System
(Ventana Medical Systems, Tucson, AZ, USA) with
antibody visualization using the OptiView DAB IHC
Detection Kit (Ventana Medical Systems) for PD-L1,
PMS2, and UltraView DAB IHC Detection Kit (Ventana
Medical Systems) for MSH2, MSH6, MLH-1 according to
the manufacturer’s instructions. All IHC stained slides and
corresponding H&E-stained slides were digitally scanned
[3DHistech Panoramic 250 Flash (3DHISTECH Ltd.,
Budapest, Hungary)].
2.2.1. Evaluation of PD-L1 expression
Expression of PD-L1 was evaluated by IHC using rabbit
monoclonal anti-PD-L1 clone SP263 [Ventana Medical
Systems, Inc., Tucson, Arizona, USA; retrieval: EDTA 60’;
incubation: 120’; ready to use [RTU] dilution]. Human
placental tissue was utilized as a positive control. As we
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Figure 1. Flow chart illustrating the inclusion and exclusion criteria of cases in the study.

described below, PD-L1 stained sections were evaluated by
using assay scoring algorithms that were published for PDL1 clone SP263 [12].
Initially, H&E-stained sections were screened to
determine the immune cell proportion (ICP) for each slide
which was the percentage of the tumour area occupied
by any tumour-associated immune cells. Immune cells
adjacent to the tumour and infiltrating the tumour (IC)
were taken into consideration. And cases were classified
into three groups concerning ICP (group 1: ≤ 5%, group 2:
6%–10%, group 3: (>10%).
PD-L1 status was determined by the percentage of
tumour cells (TC+) with any membranous staining (partial
or complete) or by the percentage of tumour-associated
immune cells with membranous/cytoplasmic/punctate
staining (IC+). IC+ and TC+ were scored as deciles and
quartiles and categorised as “negative/low” (Figures 2A
and 2B) and “high” (Figures 3A and 3B) expressions.
PD-L1 expression was classified as “high”, if any of the
followings were met: ≥25% of TC exhibit membranous
staining; or ICP > 1% and IC+ ≥ 25%; or ICP = 1% and
IC+ = 100%. Conditions other than these were classified as
negative/low PD-L1 expression.
2.2.2. Evaluation of DNA MMR proteins expression
DNA MMR family include several proteins. We evaluated
the expressions of 4 major MMR proteins -MLH1,
MSH2, PMS2, MSH6- by immunohistochemistry,
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since these proteins are the most commonly studied of
DNA MMR family and have been found to be highly
associated with microsatellite instability. Expression
of DNA MMR proteins was investigated by IHC using
MLH1 (mouse monoclonal primary antibody; clone M1;
retrieval: EDTA 60’; incubation: 48’; ready to use [RTU]
dilution), MSH2 (mouse monoclonal primary antibody;
clone G219–1129; retrieval: EDTA 60’; incubation:
40’; ready to use [RTU] dilution), MSH6 (mouse
monoclonal primary antibody; clone 44; retrieval:
EDTA 90’; incubation: 56’; ready to use [RTU] dilution),
and PMS2 (rabbit monoclonal primary antibody; clone
EPR3947; retrieval: EDTA 60’; incubation: 60’; ready
to use [RTU] dilution). Normal colonic mucosa was
utilized as a positive control. Each digitally scanned
slide was reviewed and then the percentage of positively
stained TC was determined. Inevaluable areas due to
necrosis or cautery/crush artifacts were disregarded.
Lymphocytes and some stromal cells served as the
internal positive control. The immunostaining was
repeated for cases without internal control staining (13
cases). Immunostainings for each DNA MMR proteins
were classified as “absent” if the case had no positively
(0%) stained TC nuclei, “reduced” (Figure 4A) if ≤30%
of TC nuclei stained positively, and “preserved” (Figure
4B) if >30% of tumour cell nuclei stained positively
[13,14].
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Figure 2. Negative/low (<25%) PD-L1 expression. Corresponding H&E (A, 400×) and PD-L1 (B, 400×) stained sections.
Arrow: Positive staining in immune cells.

Figure 3. High (≥25%) PD-L1 expression. Corresponding H&E (A, 200×) and PD-L1 (B, 200×) stained sections. Arrow:
Positive staining in immune cells.

Figure 4. Reduced (≤30%) expression of DNA MMR protein (MSH6, 400×) (A) and preserved (>30%) expression of DNA
MMR protein (MSH2, 100×) (B). Arrow: Positive staining in tumour cells.
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2.3. MSI testing
2.3.1. DNA extraction
DNA was extracted from 5 µm thick FFPE tissue sections.
To enrich tumour DNA, macrodissection was applied to
slides with areas containing less than 50% tumour cells.
MSI testing was performed on 57 patients. In 2 cases
(both BCG refractory), there was insufficient material
(<20% tumour cells) to extract enough DNA to perform
the analysis. For DNA extraction from FFPE tissues, the
QIAamp tissue kit (Qiagen Inc, Santa Clarita, CA) was
used according to the manufacturer’s instructions. The
corresponding normal control DNA was derived from the
nontumoural tissue of each patient.
2.3.2. PCR-based MSI testing
Normal and tumour DNA pairs were analysed for each
case by PCR-based commercial MSI testing kit developed
by Promega (MD1641 MSI Analysis System, Version 1.2).
This kit consists of 5 poly-A mononucleotide markers
(BAT-25, BAT-26, NR-21, NR-24, and MONO-27) and
two highly polymorphic pentanucleotide repeat markers
(Penta C and Penta D). The mononucleotide markers are
used for MSI determination, and the pentanucleotide
markers are used to detect potential sample mix-ups
and/or contamination. PCR products were analysed by
capillary electrophoresis using ABI 3500 Genetic Analyzer
(Applied Biosystems, Forster City, CA). Microsatellite
region lengths were compared between paired normal and
tumour tissue for each patient.
2.3.3. Microsatellite analysis system with Promega panel
We interpreted MSI testing as follows: microsatellite
instability at ≥2 mononucleotide loci as MSI-high
(MSI-H), instability at a single mononucleotide locus as
MSI-low (MSI-L), and no instability at any of the loci as
microsatellite stable (MSS) (Figure 5) [15].
2.4. Statistical analysis
All analyses were performed by using SPSS software v.20.0
(IBM, Armonk, NY, USA). Shapiro-Wilks test was used to
assess the assumption of normality. Continuous variables
that do not have normal distribution were expressed
as median (minimum-maximum). Also, categorical
variables were summarised as counts (percentages). For
nonnormally distributed continuous variables, differences
between groups were tested using Mann-Whitney U
test. For pre- and posttreatment comparisons in BCG
nonresponsive group, the Wilcoxon sign rank test was
used for continuous variables, while McNemar’s test
was performed for categorical variables. Associations
between categorical variables were determined by chisquare analysis or Fisher’s exact test, while associations
between continuous variables were determined by Pearson
correlation analysis. p-values of less than 0.05 were
considered statistically significant.
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3. Results
3.1. Patient characteristics
The mean age of the patients was 67.74 (48–85) years
[69.73 (52–85) years in BCG responsive group and 66.34
(48–84) years in BCG nonresponsive group; p = 0.139].
The clinicopathological features are summarised in Table 1.
Multifocality was more in the BCG nonresponsive
group (Table 1; p=0.001). 22 (75.9%) of 29 BCG
nonresponsive patients had multiple tumour foci. BCG
failure was higher in the group with deep lamina propria
invasion (shown in Table 1; p=0.038).
ICP showed a difference neither between pretreatment
biopsies of the BCG nonresponders and the BCG
responders nor the pre- and posttreatment biopsies of the
BCG nonresponders (p=0.922 and p=0.352, respectively).
There was not any statistically significant difference
between BCG responders and BCG nonresponders among
pT1 patients, in terms of the extent of tumour invasion
(focal: 1 focus, multifocal: >1 focus) or long diameter of
largest invasive focus (<2mm, ≥2mm). ICP was lower in
tumours with concomitant carcinoma in situ (CIS) (n:10)
compared to cases without CIS (n:49) (p=0.018).
3.2. PD-L1 expression
All biopsies showed negative/low PD-L1 expression in TC.
The distribution of ICP groups and PD-L1 expression of
IC in pretreatment biopsies of both BCG nonresponsive
and BCG responsive cases are summarised in Table 2.
PD-L1 expression did not show any significant
difference between the pre- and posttreatment TUR-B
specimens of the BCG nonresponder group (shown in
Table 3) or between the pretreatment TUR-B specimens of
BCG nonresponder and the BCG responder groups (p =
0.508, p = 0.708, respectively).
High PD-L1 expression in IC was found more common
in T1 tumours than Ta tumours (Figure 6; p = 0.008). A
positive correlation was observed between the percentage
of ICP and PD-L1 expression in IC (Pearson correlation:
0.428; p = 0.001). There was no relation between PD-L1
expression in IC and the histopathologic features evaluated
(depth of lamina propria invasion, long diameter of largest
invasive focus, and the extent of lamina propria invasion
or the presence of concomitant carcinoma in situ) (p =
0.313; p = 0.859; p = 0.603, p = 1.000, respectively).
3.3. DNA MMR protein expressions
Reduced DNA MMR protein expression was found to
be significantly higher in the pretreatment biopsies of
BCG-responsive group than the BCG nonresponsive
tumour group (p = 0.022). Reduced expression of DNA
MMR proteins was detected in 24 (40.7%) pretreatment
TUR-B specimens and 17 (70.8%) of 24 cases were BCG
responders (detailed in Table 4; p = 0.022). We did not
observe the total loss of DNA MMR proteins in any case.

SALMAN et al. / Turk J Med Sci

Figure 5. MSI testing. Length distribution of microsatellite regions on five mononucleotide repeat loci (NR-21, BAT-26, BAT-25, NR24, MONO-27) were compared between tumour (as shown below) and matched normal tissue (as shown above). No instability was
detected in any locus in any of the cases. All cases were microsatellite stable (MSS).

Cases with reduced expression of DNA MMR proteins
were as follows: isolated MSH6 (n = 11), isolated PMS2
(n = 6), both MSH6 and PMS2 (n = 5), combined MSH2
and MSH6 (n = 1), and one case with reduced expression

of MSH2, MSH6, and PMS2. No subclonal staining loss
(tumour area with abrupt loss of staining) was observed
in any of the cases with reduced DNA MMR protein
expression.
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Table 1. Patient demographics.

Total n (%)

BCG
responsive group n (%)

BCG
nonresponsive group n (%)

Female

6 (10.1)

5 (16.7)

1 (3.4)

Male

53 (89.8)

25 (83.3)

28 (96.6)

Solitary

26 (44)

19 (63.4)

7 (24.1)

Multiple

32 (54.3)

10 (33.3)

22 (75.9)

Missing Data

1 (1.7)

1 (3.3)

0 (0)

< 3cm

13 (22)

7 (23.3)

6 (20.7)

≥ 3cm

45 (76.3)

22 (73.4)

23(79.3)

Missing data

1 (1.7)

1(3.3)

0 (0)

Mild

27 (45.8)

15 (50)

12 (41.4)

Prominent

32 (54.2)

15 (50)

17 (58.6)

Clinicopathological features

p-value

Sex
0.195

Multifocality
0.001

Tumour size
0.7529

Nuclear pleomorphism
0.506

Presence of concomitant carcinoma in situ (CIS)
Absent

49 (83)

25 (83.3)

24 (82.8)

Present

10 (17)

5 (16.7)

5 (17.2)

pTa

8 (13.6)

3 (10)

5 (17.2)

pT1

51 (86.4)

27 (90)

24 (82.8)

1.000

Tumour stage (pT)
0.472

Depth of lamina propria invasion in pT1 patients
Superficial l. propria

33 (64.7)

21 (77.8)

12 (50)

Deep l. propria

18 (35.3)

6 (22.2)

12 (50)

Focal (1 Focus)

28 (55)

15 (55.6)

13 (54.1)

Multifocal (>1 Focus)

23 (45)

12 (44.4)

11 (45.8)

0.038

The extent of invasion in pT1 patients
0.774

Long diameter of largest invasion focus in pT1 patients
<2 mm

32 (62.7)

18 (66.7)

14 (58.3)

≥2 mm

19 (37.3)

9 (33.3)

10 (41.7)

0.585

Table 2. The distribution of ICP groups and PD-L1 expression of IC in pretreatment TUR-B specimens of both BCG nonresponsive and
BCG responsive cases (n = 59).

Evaluation

n (%)

BCG
responsive group n (%)

BCG
p-value
nonresponsive group n (%)

ICP group 1 (≤5% ICP)

34 (57.6)

17 (56.6)

15 (51.7)

ICP group 2 (6%–10% ICP)

13 (22)

8 (26.6)

6 (20.6)

ICP group 3 (>10% ICP)

12 (20.4)

5 (16.8)

8 (27.7)

Low PD-L1 in IC

25 (42.4)

12 (40)

13 (44.8)

High PD-L1 in IC (≥25%)

34 (57.6)

18 (60)

16 (55.2)
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0.703

0.708
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Table 3. Comparison between pretreatment and posttreatment TUR-B specimens of BCG nonresponders in terms of PD-L1 expression
status.
PD-L1 expression in pretreatment and posttreatment TUR-B specimens of BCG nonresponders

n (%)

Cases with high PD-L1 expression in the pretreatment TUR-B specimen and negative/low PD-L1 expression in the
posttreatment TUR-B specimen

6 (22.2)

Cases with negative/low PD-L1 expression in the pretreatment TUR-B specimen and high PD-L1 expression in the
posttreatment TUR-B specimen

3 (11.1)

Cases with negative/low PD-L1 expression in both of pretreatment and posttreatment TUR-B specimens

8 (29.7)

Cases with high PD-L1 expression in both of pretreatment and posttreatment TUR-B specimens

10 (37)

Figure 6. Comparative scheme of PD-L1 expression in IC in stage Ta
and T1 urothelial carcinoma cases (n: 59; p = 0.008).
Table 4. The relationship between reduced DNA MMR protein expression and response to BCG therapy (p = 0.022).

DNA MMR protein expression

BCG responsive group
(n = 30) n (%)

BCG nonresponsive group Total (n = 59)
(n = 29) n (%)
n (%)

Reduced expression

17 (70.8)

7 (29.2)

24 (100)

Isolated MSH6

8 (72.7)

3 (27.3)

11 (100)

Isolated PMS2

5 (83.3)

1 (16.7)

6 (100)

MSH2 and MSH6

0 (0)

1 (100)

1 (100)

PMS2 and MSH6

3 (60)

2 (40)

5 (100)

PMS2, MSH2, and MSH6

1 (100)

0 (0)

1 (100)

Preserved expression

13 (37.2)

22 (62.8)

35 (100)

There was no relation between reduced expression of
DNA MMR proteins and increased rate of ICP or high PDL1 expression (p = 0.778, p = 0.891, respectively).
3.4. MSI testing
Two of the cases were not included in the microsatellite
analysis. One of the cases did not have any normal tissue
and the other one had an extremely low tumour ratio
(<20%). MSI testing was performed in samples of 57
patients and all cases were microsatellite stable (MSS).

4. Discussion
Recently, it has been shown that tumour cells can escape
from the antitumour response of the immune system by
using the mechanisms that protect normal tissues from
the immune system. Immune checkpoint inhibitor (ICI)
treatments, in which these mechanisms are blocked, have
come up as alternative treatment approaches in various
cancer types. Antibodies that block proteins in this pathway
are intended to increase the effectiveness of T cell response
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against the tumour cells. Blockage of these immune escape
mechanisms by monoclonal antibodies has shown to be a
promising method in the treatment of many malignancies,
including advanced urothelial cancer [16]. Since the
antitumour effect of BCG occurs with the activation of T
cells against tumour cells, an immune escape mechanism
similar to that described above may also underlie BCG
unresponsiveness. If this mechanism is found to be
implicated in the BCG unresponsiveness, antibodies that
block proteins in this pathway can be used in combination
with BCG therapy to increase the effectiveness of it, or
ICIs can promise hope for BCG unresponsive urothelial
carcinomas as an alternative treatment approach.
On the other hand, MSI is known to be a biomarker
in determining the response to the immune checkpoint
inhibitors [9]. It has been reported that MSI-H tumours
have increased mutation load due to the MMR defects
and this results in a more intense immune response. Thus
MSI-H tumours show higher PD-L1 expression and they
have shown to be suitable candidates for ICI therapy
[9,17,18].
In the present study, we investigated whether PD-L1
mediated immune escape mechanisms have any role on
the BCG unresponsiveness of NMIBCs and whether status
of MSI/MMR defect predicts BCG response of this tumour
group.
In bladder carcinoma, the rate of PD-L1 positivity
in tumour cells ranges from 4.3% to 100% in published
studies [19-24]. Usage of the different PD-L1 clones or
thresholds of positivity and the varying cell type in which
immunostaining was evaluated could be the cause of
different results in previous studies. This leads to difficulties
in the interpretation and comparison of the results of these
studies. In this study, PD-L1 clone SP263, which is in use
to evaluate the clinical applicability of durvalumab, one of
the Food and Drug Administration (FDA)-approved ICIs
for the treatment of bladder carcinomas, was used. In our
study, none of the cases showed high PD-L1 expression
in TCs. We found a positive correlation between the
percentage of ICs and PD-L1 expression of ICs and high
PD-L1 expression in ICs was more frequent in T1 tumours
than Ta tumours (p = 0.008) in accordance with the results
in the literature [16,20,22,24-26]. This finding suggests that
the PD-1/PD-L1 mediated immune escape mechanism of
tumour cells may have a role in the progression of bladder
carcinomas.
Comparison between pretreatment and posttreatment
biopsies of BCG nonresponsive patients showed no
difference in terms of IC ratio and this finding showed that
the targeted immune response by BCG instillation could
not be achieved in these patients.
Based on the question of whether the BCG
unresponsiveness in NMIBCs is a result of the immune
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escape of the tumour cells by PD-1/PD-L1 interaction,
we made an investigation by two ways. We compared
PD-L1 expression between pretreatment biopsies of BCGresponsive and BCG-unresponsive groups of NMIBCs
and between pretreatment and posttreatment biopsies of
BCG unresponsive NMIBCs. There are different results in
the literature regarding this issue. In one study, increased
PD-L1 expression was detected in posttreatment biopsies
[21]. However, there are also studies reporting that PD-L1
expression decreased after the instillation of BCG [22,26]
or that there was no relationship between PD-L1 expression
and BCG treatment [16,19,25]. None of them, but two, made
a comparative assessment of PD-L1 expression between
pretreatment and posttreatment biopsies, specifically
within the tumour group with BCG failure. One of them
reported widespread and strong PD-L1 expression in BCG
granuloma areas in recurrence biopsies of BCG refractory
cases [23]. In the other more recent study, posttreatment
PD-L1 expression (with Clone: SP142, Ventana) levels
on IC significantly decreased after BCG immunotherapy
in patients with refractory recurrence, while it remained
stable in patients who upstaged to muscle-invasive
disease or subsequently developed metastasis after BCG
treatment. Hence, as a result of this study, it has been
reported that the salvage anti-PD-L1 therapy following
BCG failure might be limited in this patient group with
BCG refractory recurrence. [26]. In our study, there was
no difference between pretreatment and posttreatment
PD-L1 expression of ICs or TCs in cases with BCG failure.
The absence of the expected increase in PD-L1 expression
after treatment indicated that the PD-1/PD-L1 mediated
immune escape mechanism does not have any role in
BCG failure. In a very recently published study of BCGresponder and nonresponder urothelial carcinoma in situ
cases, no difference in terms of PD-L1 SP263 or SP142
clone expression between the BCG responder and BCGunresponsive patient group was found, but PD-L1 22C3
clone expression of tumour cells was found to be increased
in posttreatment biopsies of BCG unresponsive cases and
it has been suggested that PD-L1 22C3 expression may
identify CIS cases that fail the BCG therapy [27].
Historically, MSI was first identified in tumours of
patients with Lynch syndrome. Urothelial carcinoma in
the upper urinary tract occurs 14 times more frequently
in Lynch syndrome families than the normal population,
but there is no such relationship for urothelial carcinoma
of the bladder [28]. In studies investigating the frequency
of MSI in urothelial carcinoma of the bladder, various
(mono-, di- tri- or tetranucleotide) panels have been used,
and the frequency of MSI has been reported between 0%
and 100% [13,29-37]. These variations are likely due to the
differences in microsatellite panels, criteria of MSI-H, and
properties of the patient population [37]
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Immunohistochemistry is well correlated with the MSI
phenotype and can be used to determine MSI status, as
a quick and cheap method. In colourectal carcinomas,
tumours that have nuclear staining with MMR proteins,
even focal/heterogeneous, are evaluated as MSS [38].
But it has recently been shown that microsatellite
instability is not always a homogeneous event throughout
the tumour in sporadic colourectal carcinomas. Joost et al.
categorised the heterogeneous MMR protein expression of
colourectal carcinomas in three subtypes: intraglandular
(staining loss within or in-between glandular structures),
clonal (staining loss in whole glands or groups of glands),
and compartmental (staining loss in larger tumour areas/
compartments or between different tumour blocks). They
performed MSI analysis separately both in tumour areas
with intact MMR expression and with loss of expression and,
MSI-H was detected only in tumour areas with loss of MMR
expression. [39]. This finding revealed the subclonal MSI-H
status in tumours, and brought up the need for MSI analysis
including areas only with the loss of MMR expression for
more accurate results in MSI analysis of tumours [39,40].
There are conflicting results of studies investigating
the relationship between MMR protein expression and
MSI status in bladder carcinomas. A previous study
reported that the reduced expression of MMR proteins in
urothelial carcinomas of the bladder correlated with MSI
[29], conversely, some publications reported that there
was no correlation between reduced expression and MSI
[13,33]. In the present study, none of the cases had a total
loss of expression of MMR proteins by IHC, but reduced
expression of DNA MMR proteins was observed in 40.7%
of total cases. Since reduced / heterogeneous MMR protein
expression in our cases was of intraglandular heterogeneity
type, MMR positive and negative cells were intertwined,
and it could not be possible to perform an isolated PCR
analysis by focusing only on MMR negative cells. Further
analysis by a technique of single-cell capturing in these
areas would enable us to determine the MSI status of
these MMR negative cells; however, we could not have the
chance of this advanced technique.
MSI is known to be a biomarker in determining the
response to the ICIs [9]. It has been shown that there is a
correlation between MSI-H status and PD-L1 expression in
MSI-H tumours, such as gastrointestinal and endometrial
carcinomas [17,18]. However, some studies reported that
there is no such correlation in tumours where MSI is rarer,
such as breast and lung cancer [41,42]. In compatible with
that, there was not any correlation between reduced MMR
expression and the rate of ICP or PD-L1 expression in the
present study, as all cases with reduced expression of MMR
protein were MSS by PCR fragment analysis.
Recently, tumour mutation burden, neoantigen load,
and the presence of mutations in DNA damage response

genes have been identified as promising biomarkers of
benefit from immunotherapy with immune checkpoint
inhibitors in several malignancies, including urothelial
carcinoma [43]. The presence of deleterious mutations
in DNA damage response genes was also reported
to be associated with improved outcomes after BCG
immunotherapy and tumour mutation burden, high
neoantigen load were found to be higher in the BCGresponsive group compared to BCG-unresponsive patients.
In the present study, we investigated the role of DNA
MMR gene expression, a gene group that is also involved
in the DNA damage response, in predicting the response
of NMIBC cases to BCG therapy and the expression of
DNA MMR genes were evaluated at the protein level by
using immunohistochemistry, which is an easier and
cheaper method. As a prominent finding of this study,
a statistically significant correlation between reduced
DNA MMR protein expression and the responsiveness to
BCG therapy was detected (p = 0.022). Our study is the
first to investigate the relationship between DNA MMR
gene expression status and response to BCG therapy
in NMIBC cases receiving BCG therapy and it can be
suggested that the evaluation of DNA MMR protein
expression may be useful in predicting NMIBC cases
that will respond well to BCG therapy. Since there is no
validated predictive biomarker to guide patient selection
for BCG immunotherapy, this important finding of the
present study might promise hope for the management of
NMIBC cases by using a very cheap and easy technique. A
better antitumour activity of BCG in NMIBC cases with
decreased DNA MMR gene expression may be related to
the cancer neoantigens caused by tumour gene mutations
accumulating as a result of DNA repair defects [44].
5. Conclusion
Our study is the first to investigate the role of DNA
MMR expression, microsatellite instability, and PD-L1
expression, all together, in the BCG failure of NMIBC
cases. Our findings suggest that the PD-1/PD-L1
mediated immune escape mechanism may have a role as
an underlying mechanism in the progression of urothelial
carcinomas, whereas it does not seem to have any role in
the BCG failure. Our study revealed that the evaluation of
DNA MMR protein expression may be useful in predicting
NMIBC cases that will respond well to BCG therapy and
a better antitumour activity of BCG in NMIBC cases with
decreased DNA MMR gene expression may be related to
the cancer neoantigens caused by tumour gene mutations
accumulating as a result of defective DNA repair. Since
there is no validated predictive biomarker to guide
patient selection for BCG immunotherapy, this important
finding of the present study might promise hope for the
management of NMIBC cases by using a very cheap and
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easy technique. However, our study had some limitations
such as relatively small number of cases and retrospective
design. Further studies with larger case series may
contribute to our findings.
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